Mabwell has announced the approval of clinical trial application for 9MW2921 by the National Medical Products Administration (NMPA) for the treatment of advanced solid tumours. 9MW2921 is developed by Mabwell's novel antibody-drug conjugate plateform IDDC™.
9MW2921 is an advanced antibody-drug conjugate (ADC) that has been developed using the IDDC™ (Interchain-Disulfide Drug Conjugate) platform specifically for the treatment of solid tumours.
9MW2921 exhibits specific binding to antigens present on the cell membrane surface of tumour cells. This specific binding is facilitated by the antibody component of the ADC, which recognises and attaches to the target antigens.
9MW2921 is a pharmaceutical compound that possesses several desirable characteristics. It is characterised by a stable structure, homogeneous composition, and high purity, making it suitable for industrial scale-up.
9MW2921 demonstrates an improved bystander killing effect. The bystander effect refers to the ability of a drug to induce cell death in neighbouring cells, even if they do not directly interact with the drug. By enhancing this effect, 9MW2921 can increase its overall efficacy by attacking not only the target cells but also the surrounding tumour microenvironment
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!